LANGHORNE, Pa., June 15, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO, will participate in a virtual fireside chat with Naz Rahman, CFA, Vice President, Senior Equity Research Analyst, at the Maxim Group Virtual Healthcare Conference being held on June 20th - 22nd.
Maxim Group Fireside Chat Details
Date: June 20, 2023
Presentation Time: 3:30 P.M. ET
Registration: HERE
The conference is being hosted by M-Vest, a division of Maxim. If you would like to schedule a meeting with NEXGEL, please contact your Maxim representative or send an email to This email address is being protected from spambots. You need JavaScript enabled to view it..
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contacts:
Kelly Knobeck
Director of Consumer Products
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.65 |
Daily Change: | 0.03 1.15 |
Daily Volume: | 9,508 |
Market Cap: | US$17.990M |
May 13, 2025 November 13, 2024 November 11, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load